[Correspondence] HIV moments and pre-exposure prophylaxis
The PROUD study (Jan 2, p 53)1 recently reported confirmatory evidence that oral tenofovir disoproxil fumarate–emtricitabine pre-exposure prophylaxis (PrEP) protects men who have sex with men against HIV acquisition. The study showed unexpectedly high HIV incidence (9·0 infections per 100 person-years) in men who asked for PrEP and who were asked to defer. The HIV incidence in this group was three times what was expected on the basis of epidemic trends. This finding is consistent with our observations that people at higher risk for HIV infection were more likely to seek PrEP services, stay in care, and be adherent.